News

Daridorexant 25 mg and 50 mg had the best results in comparison with placebo.

Over 21 million children and adolescents aged 12–20 years had received 1 or more doses of a COVID-19 vaccine, amounting to 1 reported case of MIS-C per million vaccinated individuals in this age group.

The estimated mean change in body weight from baseline to week 68 was -13.2% in the semaglutide 2.4 mg group versus -2.1% in the placebo group.

the high prevalence of the condition in middle-age and elderly populations has led to frequent updates on the long-term efficacy of current therapies and new investigational agents.

The Supplemental New Drug Application was based on the results of numerous clinical trials.

The esteemed pediatric pulmonologist of Bridge Atlanta Medical Center drops by Lungcast to discuss the disparities that continue to exist in childhood asthma.

Melatonin is seen as the most promising treatment in this patient population.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

With the field already booming with capability, a Penn Medicine expert discusses her team's research into finding the right tools for the right patients and clinicians.

An executive with Seqirus discusses the company's work to address age-related flu severity risks.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

Future clinical trials may be necessary to confirm if 1 treatment is superior to the other to a clinically relevant degree in patients with thyroid eye disease.

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

A pilot trial from Perelman showed patients were far more likely to provide blood pressure levels via text than a standard online patient portal.

A look into the research and prospects Seqirus looks to fulfill with the technology platofrm.

Telemedicine use has become more prevalent during the ongoing COVID-19 pandemic. However, there is limited data on patient satisfaction with tele-dermatology

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

The safety syringe and auto-injector provide patients with psoriasis with 2 options for the self-administration of bimekizumab.

In data presented at ECCO 2022, investigators identified the optimal infliximab cut-off level was 4 μg/ml.

AHN is one of the few hospitals who have implemented this type of program to treat IBD complications.

There is no clinically meaningful differences in safety and efficacy between biologics and biosimilars.

Guselkumab is being studied as a treatment for both Crohn's disease and ulcerative colitis.

The data presented during ECCO 2022 involved IBD patients both in Hong Kong and the US.

There is concerns over missed early screenings for gastrointestinal cancers due to the COVID-19 pandemic.

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

The efficacy rates at weeks 12 and 52 were numerically lower in ileal only Crohn’s disease relative to colonic only and ileal-colonic.

A higher proportion of patients treated with mirikizumab achieved clinical remission at week 12 compared to placebo.

Rare disease pyruvate kinase deficiency received first approved disease-modifying therapy.